CD8A and neoplasm: This has been proven in the 4T1 tumor mouse model, and, most importantly, this strategy can effectively improve the anti-PD-1 therapy resistance and inhibit lung metastasis by activating CD8 + T cells and decreasing the counts of MDSCs (53.55% vs. 19.9).